FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Arjona Ferreira Juan Camilo		 2. Issuer Name and Ticker or Trading Symbol

Myovant Sciences Ltd. [ MYOV ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
Chief Medical Officer
(Last)          (First)          (Middle)

C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR		 3. Date of Earliest Transaction (MM/DD/YYYY)

8/26/2019
(Street)

BRISBANE, CA 94005
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
 6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Shares  8/26/2019    A    47570 (1) A $0.00  57310  D   

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy)  $10.60  8/26/2019    D        260000 (2)   (3) 8/14/2027  Common Shares  260000  $0.00  0  D   
Stock Option (Right to Buy)  $7.78  8/26/2019    A     260000 (2)      (3) 8/14/2027  Common Shares  260000  $0.00  260000  D   
Stock Option (Right to Buy)  $21.87  8/26/2019    D        87050 (2)   (4) 4/15/2028  Common Shares  87050  $0.00  0  D   
Stock Option (Right to Buy)  $7.78  8/26/2019    A     87050 (2)      (4) 4/15/2028  Common Shares  87050  $0.00  87050  D   
Stock Option (Right to Buy)  $24.44  8/26/2019    D        66130 (2)   (5) 4/4/2029  Common Shares  66130  $0.00  0  D   
Stock Option (Right to Buy)  $7.78  8/26/2019    A     66130 (2)      (5) 4/4/2029  Common Shares  66130  $0.00  66130  D   

Explanation of Responses:
(1)  The Common Shares are to be acquired upon the vesting of certain Restricted Stock Units ("RSUs") granted to the Reporting Person. The RSUs shall vest as follows: (i) 1/3 of the total shares subject to the RSUs shall vest at the later occurrence of (a) the achievement of certain milestones and (b) the first anniversary of the grant date; and (ii) 2/3 of the total shares subject to the RSUs shall vest as follows: 1/8 vesting on the first anniversary of the grant date and 7/8 vesting in seven even installments each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date.
(2)  Each reported acquisition and disposition of an option for the like number of shares consisted of an amendment to an outstanding option, resulting in the deemed cancellation of the "old" option and grant of a replacement option.
(3)  1/4 of the common shares underlying this option vested on August 15, 2018, and 1/16 of the common shares underlying this option vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date. The replacement option provides that the Reporting Person cannot exercise the currently vested portion of the replacement option for 12 months commencing on August 26, 2019, subject to certain exceptions provided by the Reporting Person's applicable option agreement.
(4)  1/4 of the common shares underlying this option vested on April 16, 2019, and 1/16 of the common shares underlying this option vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date. The replacement option provides that the Reporting Person cannot exercise the currently vested portion of the replacement option for 12 months commencing on August 26, 2019, subject to certain exceptions provided by the Reporting Person's applicable option agreement.
(5)  1/4 of the common shares underlying this option vest on April 5, 2020, and 1/16 of the common shares underlying this option vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Arjona Ferreira Juan Camilo
C/O MYOVANT SCIENCES INC.
2000 SIERRA POINT PARKWAY, 9TH FLOOR
BRISBANE, CA 94005

Chief Medical Officer

Signatures
/s/ Matthew Lang, Attorney-in-fact 8/27/2019
**Signature of Reporting Person Date


Myovant Sciences (NYSE:MYOV)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Myovant Sciences Charts.
Myovant Sciences (NYSE:MYOV)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Myovant Sciences Charts.
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....